Neurotech International Ltd
Company Profile
Business description
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
Contact
55 Collins Street
Suite 102, Level 1
MelbourneVIC3000
AUST: +61 394983132
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
18
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,686.30 | 8.30 | -0.10% |
| CAC 40 | 7,981.07 | 27.30 | 0.34% |
| DAX 40 | 23,278.85 | 115.93 | 0.50% |
| Dow JONES (US) | 45,752.26 | 339.48 | -0.74% |
| FTSE 100 | 9,527.65 | 20.24 | 0.21% |
| HKSE | 25,269.21 | 566.36 | -2.19% |
| NASDAQ | 22,078.05 | 486.18 | -2.15% |
| Nikkei 225 | 48,625.88 | 1,198.06 | -2.40% |
| NZX 50 Index | 13,419.40 | 20.00 | -0.15% |
| S&P 500 | 6,538.76 | 103.40 | -1.56% |
| S&P/ASX 200 | 8,416.50 | 0.00 | 0.00% |
| SSE Composite Index | 3,834.89 | 96.16 | -2.45% |